. Author manuscript; available in PMC: 2007 Jun 18.

Published in final edited form as: Int J Radiat Oncol Biol Phys. 2005 Oct 19;64(2):518–526. doi: 10.1016/j.ijrobp.2005.07.970

Table 1. Patient characteristics.

Type	Subgroup	Arm I^*	Arm II^*
Gleason score	5–6	15 (30%)	24 (48%)
	7	24 (48%)	18 (36%)
	8–10	11 (22%)	8 (16%)
T stage	T1–T2	43 (86%)	43 (86%)
	T3	7 (14%)	7 (14%)
iPSA	<10 ng/mL	30 (60%)	26 (52%)
	10–20 ng/mL	15 (30%)	16 (32%)
	>20 ng/mL	5 (10%)	8 (16%)
AD	No	28 (56%)	28 (56%)
	Yes	22 (44%)	22 (44%)
Risk group	Intermediate	32 (64%)	33 (66%)
	High	18 (36%)	17 (34%)

Abbreviations: iPSA = initial pretreatment PSA; AD = androgen deprivation (intermediate-risk patients were allowed to have up to 4 months of neoadjuvant AD prior randomization and high risk patients were planned to receive 2 years of AD).

Number (percent) shown. There were no significant differences between the arms.